Agilent Technologies, Inc. (NYSE:A) Position Reduced by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. decreased its position in Agilent Technologies, Inc. (NYSE:A) by 0.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 18,426 shares of the medical research company’s stock after selling 150 shares during the period. John G Ullman & Associates Inc.’s holdings in Agilent Technologies were worth $2,736,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in A. Price T Rowe Associates Inc. MD grew its stake in Agilent Technologies by 13.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after acquiring an additional 809,149 shares in the last quarter. Marshall Wace LLP lifted its stake in Agilent Technologies by 48.6% in the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock valued at $124,073,000 after acquiring an additional 313,155 shares during the last quarter. Jennison Associates LLC grew its position in Agilent Technologies by 63.3% in the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock worth $87,075,000 after acquiring an additional 227,431 shares in the last quarter. Finally, Impax Asset Management Group plc raised its holdings in shares of Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock valued at $396,088,000 after purchasing an additional 203,234 shares in the last quarter.

Analyst Ratings Changes

A has been the topic of several recent research reports. Citigroup raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. UBS Group lifted their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Evercore ISI raised their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Stifel Nicolaus restated a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a report on Monday, August 26th. Finally, Wells Fargo & Company started coverage on Agilent Technologies in a research note on Tuesday, August 27th. They set an “overweight” rating and a $157.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Insiders Place Their Bets

In related news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now owns 40,011 shares of the company’s stock, valued at $5,801,595. This represents a 19.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $128.57 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The stock has a 50 day moving average price of $138.06 and a 200 day moving average price of $137.76. Agilent Technologies, Inc. has a 52 week low of $121.23 and a 52 week high of $155.35. The stock has a market capitalization of $36.94 billion, a PE ratio of 26.67, a price-to-earnings-growth ratio of 5.59 and a beta of 1.07.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the business posted $1.43 earnings per share. Analysts predict that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.73%. Agilent Technologies’s payout ratio is presently 19.50%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.